image: The CRISPR-engineered cancer cells (green) migrated towards an established glioblastoma tumor site (red) over the course of 28 days in a mouse model. This material relates to a paper that appeared in the 11 July, issue of Science Translational Medicine, published by AAAS. The paper, by C. Reinshagen at Brigham and Women's Hospital in Boston, MA; and colleagues was titled, 'CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors.' view more
Credit: C. Reinshagen <i>et al., Science Translational Medicine</i> (2018)